Physician profile
Dipti H Doshi
NPI 1053325761
$29,847.58
in general payments reported to CMS, 2019-2025
24 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,067 · 2021: $1,056 · 2022: $216 · 2023: $1,193 · 2024: $7,636 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,150 · Food and Beverage: $1,790 · Travel and Lodging: $1,155 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,150.00 |
| Food and Beverage | $1,789.65 |
| Travel and Lodging | $1,155.34 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17,804.03 | 2019-2022 | |
| Glaxosmithkline, LLC. | $8,270.36 | 2021-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,941.23 | 2020-2025 | Ofev |
| Amgen INC. | $431.56 | 2019-2025 | Enbrel, Otezla, Enbrel |
| Abbvie INC. | $210.39 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $183.54 | 2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $161.00 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $149.91 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $108.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $108.05 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $77.44 | 2025 | Purified Cortrophin Gel |
| Ucb, INC. | $55.18 | 2024-2025 | Bimzelx, Cimzia |
| Boston Scientific Corporation | $54.36 | 2025 | General - Pain Management |
| Radius Health, INC. | $47.09 | 2023 | Tymlos |
| Kaleo, INC. | $46.15 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $29.50 | 2023 | Idacio |
| Celgene Corporation | $24.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.33 | 2020 | |
| Mallinckrodt Enterprises LLC | $22.47 | 2019 | |
| Lilly USA, LLC | $21.40 | 2025 | Taltz, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $21.29 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $21.17 | 2020 | |
| Scilex Pharmaceuticals INC. | $19.78 | 2025 | |
| Genentech USA, INC. | $15.67 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipti Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.